


Supplemental data

Figure S1. Impact of the galenic form (suspension or tablet) on plasma posaconazole trough concentrations (POS C_{min}). A) POS C_{min} during treatment by suspension or tablet in the whole population; B) mean POS C_{min} for each galenic form in seven switched patients.

A



B




Figure S2. Impact of diarrhea on posaconazole trough concentrations (POS Cmin) during treatment by posaconazole. Each point represents one POS-C_{min} measure and horizontal lines indicate median




Table S1. Mixed-effects model on potential determinants of within-subject variability of posaconazole (POS) trough concentrations

Variables	Univariate analysis		
	Estimate±standard error	t value	p-value
POS-tablet	0.188±0.184	1.022	0.31
Age	-0.047±0.104	-0.457	0.65
Body mass index	-0.011±0.048	-0.239	0.81
Proton pump inhibitor	0.259±0.164	1.576	0.11
Mucositis	0.008±0.133	0.062	0.95
Diarrhea	-0.190±0.128	-1.479	0.14

Table S2. Mixed-effects model on potential determinants of interpatient variability of posaconazole (POS) trough concentrations

Variables	Univariate analysis		
	estimate±standard error	t value	p-value
POS-tablet	0.023±0.182	0.127	0.90
Age	0.006±0.103	0.055	0.96
Body mass index	0.052±0.047	1.095	0.27
Proton pump inhibitor	0.137±0.163	0.843	0.40
Mucositis	-0.058±0.131	-0.442	0.66
Diarrhea	-0.058±0.125	-0.468	0.64

Table S3. Clinical features of seven patients with invasive aspergillosis

Patient	Age (yr)	Sex	Hematological malignancy	Classification of IA	POS formulation	Number of POS-C _{min}	POS C _{min} (mg/l)		
							Mean	Lower	Higher
Patient 1	69	F	Myelodysplastic syndrome	probable	suspension	3	0.9	0.1	0.9
Patient 2	19	F	Hodgkin	possible	suspension	10	0.5	0.2	2.3
Patient 3	29	M	Acute myeloid leukemia	possible	suspension	12	0.2	0.1	0.7
Patient 4	64	M	Hodgkin	possible	suspension	6	1.0	0.3	1.6
Patient 5	18	M	Idiopathic medullary aplasia	possible	tablet	25	2.7	0.1	3.5
Patient 6	58	M	Acute myeloid leukemia	probable	tablet	5	2.0	1.1	2.5
Patient 7	63	F	Acute myeloid leukemia	probable	tablet	18	2.3	0.4	3.3

IA, invasive aspergillosis; F, female; M, male; HSCT, hematopoietic stem cell transplantation; POS, posaconazole; C_{min}, trough concentration.